Core Insights - Mind Medicine (MindMed) is advancing its lead candidate MM120, an orally disintegrating tablet for treating generalized anxiety disorder (GAD) and major depressive disorder (MDD) [1] Pipeline Development - Two pivotal phase III studies, Voyage and Panorama, are currently enrolling participants for MM120 ODT in GAD, with the last new drug approval for this condition occurring in 2007 [2] - Phase II study data for MM120 ODT showed efficacy significantly surpassing the current standard of care and a favorable tolerability profile [2] - Top-line data from the Voyage study is expected in the first half of 2026, while Panorama's data is anticipated in the second half of 2026 [3] - The phase III Emerge study for MM120 ODT in MDD has enrolled faster than expected, with top-line data now projected for mid-2026, earlier than previously anticipated [3] - A second phase III study, Ascend, for MDD is planned to start in mid-2026 [3] Financial Performance - MindMed's stock has increased by 101.2% over the past six months, outperforming the industry average increase of 27.6% [4] - The company secured $258.9 million in financing, enhancing its balance sheet and enabling accelerated development of MM120 [5] Additional Pipeline Asset - MindMed's second asset, MM402, is being developed for autism spectrum disorder, with a phase II study expected to begin by the end of 2025 [5] - The year 2026 is projected to be transformational for MindMed with three pivotal data readouts anticipated [5]

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is among the Best Get Rich Fast Stocks to Buy Right Now. According to TheFly, JonesTrading initiated coverage on Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) with a ‘Buy’ rating and set a price target of $61 on December 23, signaling an upside potential of 354.21% from the current price. While anticipating “strong” clinical data from initial stages leading to positive Phase 3 results for lead asset MM120 in generalized anxiety disorder (GAD) and major depressive d ...

In this article, we will take a look at the Best Get Rich Fast Stocks to Buy Right Now.In today’s fast-paced world, everyone is prioritising investments that have both high and relatively quick returns. The idea of getting “rich fast” is often met with skepticism, and for good reason, as many believe that sustainable wealth is built over time. However, sometimes markets present opportunities that, if seized, can translate into outsized returns in a short period. Such opportunities can be assessed through ca ...

Valued at roughly $1.4 billion, the company’s shares have been drawing growing investor attention as its clinical ambitions move closer to reality. MindMed’s shares have been steadily building a strong comeback story over the past few years. Just over the past 52 weeks, shares climbed 83.5%, and momentum has clearly picked up in 2025.Alongside it, MM402, an MDMA-inspired compound, is being explored for autism spectrum disorder, aiming to address core symptoms rather than surface relief. With a pipeline cent ...

Core Viewpoint - Jones Trading initiated coverage on MindMed (NASDAQ: MNMD) with a Buy rating and a $61 price target, highlighting the company's position in the expanding field of psychedelic-based neuropsychiatric treatments [1] Group 1: Company Positioning - MindMed is well positioned to benefit from favorable trends in the development of psychedelic agents for mental health [2] - Strong clinical data from earlier-stage trials is expected to lead to positive Phase III outcomes for MindMed's lead asset, MM120, in treating generalized anxiety disorder and major depressive disorder [2] Group 2: Clinical and Regulatory Considerations - There are unique clinical and regulatory risks associated with MM120 due to its relationship with LSD, which is classified as a Schedule I substance in the United States [3] - Compelling Phase III data could support eventual regulatory approval, and LSD's long history may enhance awareness and facilitate rapid commercial uptake if approved [3] Group 3: Market Performance and Opportunities - Despite a strong stock performance in 2025, with shares up approximately 69% year to date, the market is perceived to underestimate the long-term opportunity while overestimating clinical and regulatory hurdles [4]

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top Upgrades: More bullish on the name, CFRA upgraded Pool Corp. (POOL) to Buy from Hold with a $304 price target.Piper Sandler upgraded SEI Investments (SEIC) to Overweight from Neutral with a price target of $102, up from $93, as part of a Q4 preview for the asset management group. The firm believes SEI will be a "clear benefic ...

The audio webcast replay will be available 24 hours after the webcast and active on MindMed's website for 30 days. About MindMed MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key ...

Key Takeaways Five biotech stocks are highlighted for 2026 due to late-stage trials or upcoming FDA decisions.MindMed expects multiple phase III data readouts in 2026 for its lead program MM120.Ocugen, Kyverna and Celcuity face key inflection points tied to BLAs or pivotal clinical data.After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administrati ...

Summary of Mind Medicine (MindMed) FY Conference Call Company Overview - **Company**: Mind Medicine (MindMed) (NasdaqGS:MNMD) - **Focus**: Development of psychedelic treatments for psychiatric disorders, specifically Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) [1][2] Key Industry Insights - **Market Opportunity**: The company aims to address two of the largest psychiatric disorders, MDD and GAD, which have significant unmet needs. The focus on a broader label is intended to maximize treatment opportunities and economic potential [2][3] - **Acceptance of Psychedelics**: There is a growing acceptance of psychedelic treatments among both practitioners and patients, with a notable interest from new psychiatry trainees in pursuing careers involving psychedelics [5][6][7] Clinical Development Highlights - **Drug Formulation**: The primary product, referred to as 120, is a form of LSD developed into an orally disintegrating tablet, with patents granted for its formulation and stability [9] - **Phase 2b Results in GAD**: The company reported the largest placebo-adjusted change in anxiety ever recorded, with 48% of patients in remission after a single treatment. The treatment showed rapid effects, with significant improvements observed within 24 hours [11][12][15] - **Safety Profile**: No cases of suicidal ideation were reported during the trials, and the duration of perceptual effects was well-monitored, with a focus on patient safety [17][18] Phase 3 Study Design - **Dose Selection**: The 100 microgram dose was chosen for Phase 3 studies based on a comprehensive dose-response analysis conducted in Phase 2, which showed significant efficacy without increasing adverse effects [21][22] - **Open-Label Extension**: The extension phase allows for repeat treatments based on disease severity, providing insights into long-term treatment durability [26][27] Commercialization Strategy - **Target Audience**: The initial targeting will focus on existing Spravato centers, but the company plans to expand its reach beyond these centers to capture a broader market [32][34] - **Sales Force Planning**: While specific numbers for the sales force are not yet finalized, the company emphasizes a relationship-driven approach to ensure successful adoption of the treatment [36][38] - **Payer Access**: The company is proactively engaging with payers to ensure broad access to the treatment, emphasizing the need for patient-centered approaches [39] Additional Considerations - **Operational Efficiencies**: The overlap between MDD and GAD patient populations allows for streamlined clinical trials and resource allocation [30][31] - **Future Outlook**: The company is optimistic about the potential for three readouts across GAD and MDD programs in the upcoming year, which could significantly impact its market position [31]

Summary of Mind Medicine (MindMed) FY Conference Call - December 02, 2025 Company Overview - MindMed is a leading company in the development of psychedelics for psychiatric disorders, focusing on its lead program MM120, an ODT formulation of LSD for generalized anxiety disorder (GAD) and major depressive disorder (MDD) [4][4] - The company has launched two phase 3 programs and received Breakthrough Therapy Designation in 2024, with three pivotal readouts expected in 2026 [4][4] Regulatory Interactions - Regulatory interactions with the FDA have been positive, with a collaborative approach noted between MindMed and the FDA [5][5] - Continuous engagement with the FDA has been emphasized, particularly with Tiffany Farcioni, Division Director of Psychiatry [5][5][6] Clinical Trials and Data Expectations - MindMed is confident in its timelines for multiple phase 3 data readouts, citing high engagement and enrollment in studies [10][10] - The company aims for a clinically meaningful effect size of around four points for GAD, which would be larger than any approved drug [14][15] - For MDD, a similar expectation of four points is set, with a focus on durability beyond the primary endpoint [24][24] Commercial Strategy - MindMed intends to file for approval with data from both GAD studies, emphasizing the importance of a robust data package [26][26] - The company plans to leverage existing infrastructure from Spravato, which has around 5,000-6,000 centers capable of administering similar therapies [32][32] - Profitability for providers is a key consideration, with a focus on ensuring that clinics can generate revenue while providing treatment [39][40] Financial Position and Future Outlook - Recent fundraising was driven by enthusiasm for upcoming data and to enhance operational readiness for 2026 [42][42][43] - MindMed is open to exploring partnerships outside the U.S. but aims to maintain operational flexibility and leverage its expertise in psychiatry [46][47] Key Metrics and Considerations - The company has powered its studies to detect a five-point difference in anxiety, ensuring both clinical and statistical significance for positive outcomes [17][18] - Monitoring requirements for safety during treatment are being designed to align with existing standards, such as those for Spravato [30][30] Conclusion - MindMed is positioned for a significant 2026 with multiple pivotal readouts and a strong regulatory strategy, focusing on both clinical efficacy and commercial viability [48][48]